

pln. No: 09/772,938

RECEIPT FROM PTO FOR INDICATED ITEMS

(Do <u>NOT</u> Use for New or Continuing Applications of <u>Any</u> Kind)
Use 2 postcards for all New Applns. (cont/Div/CIP, too) Use this sheet when filing CPA Atty: Thomas A. Cawley, Jr./JB:K.S. Hines

Date: June 9, 2003

	١
EDOS e D MUL	3
THE TRADERIE	? —

First Inventor: Nabil HANNA et al.	Date: June 9, 2003
First Inventor: Nabil 17 (N. V. C. a.i.	Matter No: 276658
	Client No: 37003
ENCLOSED: ⊠ Response/Amendment □ Appe	endix 🛛 Cover Sheet 🗀 Cited/Listed Documents
☐ Completion Request for R 53(f)/PC	T Nat.
# No. of Pages Abstract	
# No. of Pages Spec and Claims	
# No. of Numbered Claims <u>Only</u>	
# No. of Sheets of Drawings (Figs	
1 Set Formal 1 Se	et Informal Cover Letter
Declaration	of pages
Assignment	Cover Sheet
Small Entity Declaration	
Extension Petition (PAT-111)	
# No. of Priority Documents	
☐ IDS Letter ☐ Cited Appln(s) [
☐ PTO-1449 ☐ Cited Documen	ts
Issue Fee Transmittal Form PTO	oL-85(b) <u>in duplicate</u>
\$ Amount Requested be	Charged to our Dep. Acct. No. 03-3975
· ·	
OTHER:	
<u>Current</u> DUE DATE:	July 8, 2003

(Submit Single Copy Only)

IN THE UNITED

TES PATENT AND TRADEMARK OFFIC

PATENT APPLICATION

Nabil HANNA et al. Inventor(s): 772,938 Appln. No.: Serial No. 1 Series Code ↑

January 31, 2001 Filed: Mail Stop Non-Fee Amendment Hon. Commissioner for Patents

PO Box 1450 Alexandria, VA 22313-1450

Sir:

Group Art Unit Examiner: Atty. Dkt.

Appln. Title:

1644 276658

Phillip Gambel 1999-30-0466CP2 Client Ref

TREATMENT OF B CELL MALIGNANCIES USING COMBINATION OF B CELL DEPLETING ANTIBODY AND IMMUNE MODULATING ANTIBODY RELATED

APPLICATIONS Date: June 9, 2003

REPLY/AMENDMENT/LETTER

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim A. ⊠ NOT made B. ☐ Withdrawn C. ☐ made herewith D. ☐ made previously Plate 1256)	Claims remaining after amendment	Highest num previously pa	ber id for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
D. [] made promote,		_			x \$18/\$9 =	+ \$0	103/203
2. Total Effective Claims	21	**minus	21	1	x \$84/\$42 =	+ \$0	102/202
2. Total Effective Claims 2 ***minus 3 0 \$\times \$\tim						+ \$0	104/204
time (leave blank if this is a reissue of	pplication,	NONE		ESTATAS TE TRANSPORTE	2013年20年第2日		116/016
S. Original due Date: July 8, 2003 Petition is hereby made to extendate to cover the date this response requisite fee is attached	d the original o	lue (2 th the (2 (3	1 mo) mos) mos) mos)		+ \$0		115/215 116/216 117/217 118/218 128/228
(5 mos) \$1,9/0/\$985=							
7. Enter any previous extension fee paid since above original due date and subtract - \$0 Extension Fee					+ \$0	SA 388	
8 + \$110/\$55					+ \$0	148/248	
9. If Terminal Disclaimer attached, add Rule 20(d) Official ree					+ \$0	126 126	
10. If IDS attached requires Official Fee under Nute 37 (4), and 4 \$180 or if Rule 97(d) Request \$420(a) and 47(f) \$430(a) and 47(f) \$430(+ \$0	146/246
					+ \$0	149/249	
11. After-Final Request Fee per rules 123(a) and 17(7) x \$750/375 ea 12. No. of additional inventions for examination per Rule 129(b)					+ \$0	1179/1279	
12. No. of additional inventions for examination per rule: 150/375 + \$750/375 13. Request for Continued Examination (RCE)					+ \$0		
14. Petition fee for TOTAL FEE =					\$0		
15. 16. *If the entry in this space is less than en	try in next space, t	he "Present Ext	ra" resu , write '	It is "0". '20" in this space.			CHARGE P. ACCT

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. *** If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975) 276658 (Our Order No. 37003

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be CHARGE 3/A LEGICITY. THE CHIRUSDALINE IN HERVY QUIDALIZED AS CHARGE BY THE SPECIALITY QUIDALIZED HERSELF, U. dry missing or insumican acres (me), or asserted to the filled or which should have been filled herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or itled, of which should have Seen tittle intereval or concerning any paper med interesting, and which interpret requires order requires order requires order requires the purpose a hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos, shown above, for which purpose a hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos, shown above, for which purpose a Query: Is appeal deadline now? If

duplicate copy of this sheet is attached. This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

so, file Notice of Appeals separately

P.O. Box 10500 McLean, VA 22102 Tel: (703) 905-2000 Pillsbury Winthrop LLP Intellectual Property Group

Thomas A. Cawley, Jr., Ph.D By Atty:

Reg. No. 40944 (703) 905-2500 Fax: (703) 905-2144

Reply Pursuant to 37 C.F.R. § 1.116 Expedited Procedure Group Art Unit 1644

ITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Nabil HANNA et al.

Application Serial No. 09/772,938

Group Art Unit: 1644 Examiner: Phillip Gambel

Filed: January 31, 2001 Title: TREATMENT OF B CELL MALIGNANCIES USING COMBINATION OF B CELL DEPLETING ANTIBODY AND IMMUNE MODULATING ANTIBODY RELATED APPLICATIONS

REQUEST FOR RECONSIDERATION

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

This is in response to the official action [final rejection] dated April 8, 2003, wherein Sir: the claims were rejected under 35 U.S.C \S 103(a) as well as the doctrine of obviousness-type double patenting.